In contrast , at weeks @ and @ , the mean symptom-scale scores for trametinib decreased from baseline ( symptoms improved ) for pain ( @-@ points ) , insomnia ( @-@ points ) , and appetite loss ( @-@ points ) , whereas those for diarrhea worsened ( @-@ points ) .